Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Regulated control of gene therapies by drug induced splicing

ABSTRACT: Regulated control of gene therapies by drug induced splicing

PROVIDER: PRJNA736612 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14777583_1.fastq.gz	Fastqsanger.gz
	SRR14777583_2.fastq.gz	Fastqsanger.gz
	SRR14777584_1.fastq.gz	Fastqsanger.gz
	SRR14777584_2.fastq.gz	Fastqsanger.gz
	SRR14777585_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Regulated control of gene therapies by drug induced splicing

Project description:RNA Seq datasets from HEK293 cells treated with 25nM LMI070 To date, gene therapies for human application rely on engineered promoters that cannot be finely controlled. Here, we report a universal switch element that allows precise control for gene replacement or gene silencing after exposure to a small molecule. Importantly, these small molecule inducers are in human use, are orally bioavailable when given to animals or humans, and can reach both peripheral tissues and the brain. Moreover, the switch system (Xon) does not require the co-expression of any regulatory proteins. Using Xon, translation of desired elements for controlled gene replacement or editing machinery occurs after a single oral dose, and the robustness of expression can be controlled by drug dose and with repeated drug exposure. The ability of Xon to provide temporal control of protein expression can be adapted to cell biology applications and animal studies. Additionally, due to the oral bioavailability and safety of the drugs employed, the Xon switch provides an unprecedented opportunity to refine gene therapies for more appropriate human application.

2021-07-22 | GSE176527 | GEO

Regulated control of gene therapies by drug-induced splicing.

Project description:So far, gene therapies have relied on complex constructs that cannot be finely controlled1,2. Here we report a universal switch element that enables precise control of gene replacement or gene editing after exposure to a small molecule. The small-molecule inducers are currently in human use, are orally bioavailable when given to animals or humans and can reach both peripheral tissues and the brain. Moreover, the switch system, which we denote Xon, does not require the co-expression of any regulatory proteins. Using Xon, the translation of the desired elements for controlled gene replacement or gene editing machinery occurs after a single oral dose of the inducer, and the robustness of expression can be controlled by the drug dose, protein stability and redosing. The ability of Xon to provide temporal control of protein expression can be adapted for cell-biology applications and animal studies. Additionally, owing to the oral bioavailability and safety of the drugs used, the Xon switch system provides an unprecedented opportunity to refine and tailor the application of gene therapies in humans.

| S-EPMC8966400 | biostudies-literature

HNRNPM-regulated splicing dependencies in prostate cancer

Project description:HNRNPM-regulated splicing dependencies in prostate cancer

| PRJNA453983 | ENA

QKI regulated splicing required for cell polarity

Project description:QKI regulated splicing required for cell polarity

| PRJNA798365 | ENA

Non-canonical BIM-regulated energy metabolism determines drug-induced liver necrosis.

Project description:Non-canonical BIM-regulated energy metabolism determines drug-induced liver necrosis.

| PRJNA1013350 | ENA

Transcriptomic RNAseq drug screen in cerebrocortical cultures towards novel neurogenetic disease therapies.

Project description:Transcriptomic RNAseq drug screen in cerebrocortical cultures towards novel neurogenetic disease therapies.

| PRJNA433312 | ENA

Identification of WTAP complex-regulated alternative splicing/polyadenylation

Project description:Identification of WTAP complex-regulated alternative splicing/polyadenylation

| PRJNA702814 | ENA

Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB

Project description:This SuperSeries is composed of the following subset Series: GSE23513: Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB (HJAY) GSE23514: Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB (Exon array) Refer to individual Series

2010-09-01 | E-GEOD-23522 | biostudies-arrayexpress

Transcriptome analysis of alternative splicing events regulated by SRSF10 reveals position-dependent splicing modulation.

Project description:Splicing factor SRSF10 is known to function as a sequence-specific splicing activator. Here, we used RNA-seq coupled with bioinformatics analysis to identify the extensive splicing network regulated by SRSF10 in chicken cells. We found that SRSF10 promoted both exon inclusion and exclusion. Functionally, many of SRSF10-verified alternative exons are linked to pathways of stress and apoptosis. Importantly, reconstituted SRSF10 in knockout cells recovered wild-type splicing patterns and considerably rescued the stress-related defects. Together, our results provide mechanistic insight into SRSF10-regulated alternative splicing events in vivo and demonstrate that SRSF10 plays a crucial role in cell survival under stress conditions. RNA-seq for wide type (WT) and SRSF10-deficient (KO) chicken DT40 cells

2014-01-22 | E-GEOD-53354 | biostudies-arrayexpress

HNRNPM-regulated splicing dependencies in prostate cancer [eCLIP-Seq]

Project description:HNRNPM-regulated splicing dependencies in prostate cancer [eCLIP-Seq]

| PRJNA453984 | ENA